RYTM

Rhythm Pharmaceuticals Inc

92.57

Oct 30 • 3:59 PM ET -0.50 (-0.54%)

93.04

Aftermarket • 7:30 PM ET +0.47 (0.51%)

Healthcare Biotechnology USA Mid NASD

Peers: ACAD AARD VKTX ASND GPCR BMRN HRMY NBIX LLY NVO

| Held by: VTI VB IWM XBI VBK VXF IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT
Market Cap	6.37B
Enterprise Value	6.27B
Income	-210.22M
Sales	239.92M
Book/sh	1.50
Cash/sh	4.81
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	414
IPO	Oct 05, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	26.57
P/B	61.86
P/C	19.26
P/FCF	-
EV/EBITDA	-
EV/Sales	26.12
Quick Ratio	3.20
Current Ratio	3.45
Debt/Eq	0.51
LT Debt/Eq	0.44
Option/Short	Yes / Yes

EPS (ttm)	-3.12
EPS next Y	-0.65
EPS next Q	-0.71
EPS this Y	5.29%
EPS next Y	78.07%
EPS next 5Y	-
EPS past 3/5Y	3.66% -0.46%
Sales past 3/5Y	100.23% -
EPS Y/Y TTM	-3.31%
Sales Y/Y TTM	53.51%
EPS Q/Q	2.55%
Sales Q/Q	46.91%
Earnings	Nov 03 BMO
EPS/Sales Surpr.	9.56% 5.32%

Insider Own	3.96%
Insider Trans	-9.92%
Inst Own	110.09%
Inst Trans	5.49%
ROA	-50.70%
ROE	-199.95%
ROIC	-65.46%
Gross Margin	88.91%
Oper. Margin	-83.62%
Profit Margin	-87.62%
SMA20	3.09%
SMA50	-4.74%
SMA200	-4.66%
Trades

Shs Outstand	68.82M
Shs Float	66.13M
Short Float	16.64%
Short Ratio	16.74
Short Interest	11.00M
52W High	122.20 -24.25%
52W Low	74.50 24.26%
Volatility	2.94% 3.51%
ATR (14)	3.27
RSI (14)	50.25
Beta	2.17
Rel Volume	0.66
Avg Volume	657.39K
Volume	431,681

Perf Week	3.70%
Perf Month	-0.90%
Perf Quarter	-9.93%
Perf Half Y	13.15%
Perf YTD	-13.52%
Perf Year	-17.21%
Perf 3Y	306.54%
Perf 5Y	704.26%
Perf 10Y	-
Recom	1.20
Target Price	140.53
Prev Close	93.07
Price	92.57
Change %	-0.54%

Consensus

Strong Buy

Avg. Price Target

$140.53

Implied Upside

+51.8%

Analysts16incl. previous ratings

Rating Distribution14 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 16, 2026	Initiated	WWilliam Blair	Outperform
Sep 17, 2026	Initiated	WWolfe Research	Outperform
Sep 14, 2026	Resumed	LLeerink Partners	Outperform	$133	+43.7%
Aug 28, 2026	Initiated	DDeutsche Bank	Hold	$120	+29.6%
Jul 27, 2026	Initiated	JJP Morgan	Overweight	$145	+56.6%
Feb 19, 2026	Initiated	RRBC Capital Mkts	Outperform	$478	+416.4%
Nov 25, 2025	Initiated	CCitigroup	Buy	$136	+46.9%
Nov 05, 2025	Downgrade	OOppenheimer	Outperform → Perform
Jul 10, 2025	Initiated	GGoldman	Buy	$97	+4.8%
Jul 07, 2025	Initiated	LLeerink Partners	Outperform	$88	-4.9%
Apr 07, 2025	Upgrade	BBofA Securities	Neutral → Buy	$63	-31.9%
Mar 05, 2025	Resumed	SStifel	Buy	$78	-15.7%
Jan 02, 2025	Initiated	JJefferies	Buy	$80	-13.6%
Dec 20, 2024	Initiated	OOppenheimer	Outperform	$76	-17.9%
Oct 21, 2024	Initiated	GGuggenheim	Buy	$70	-24.4%
Sep 18, 2024	Initiated	HH.C. Wainwright	Buy	$64	-30.9%
Sep 17, 2024	Initiated	JJMP Securities	Mkt Outperform	$64	-30.9%
May 08, 2024	Downgrade	BBofA Securities	Buy → Neutral	$49 → $42	-54.6%
Dec 19, 2023	Upgrade	MMorgan Stanley	Equal-Weight → Overweight	$29 → $55	-40.6%
Aug 01, 2023	Upgrade	BBofA Securities	Neutral → Buy	$22 → $27	-70.8%

Oct-26-26 06:04PM	Rhythm's Incivri Launch Faces Its First Real Test As Street Bets On 18% Sequential Jump (Earnings Whispers)
Oct-21-26 01:16PM	Big Pharma's Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN) (FinanceWire)
08:00AM	Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 (GlobeNewswire)
Oct-13-26 07:30PM	Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity (GlobeNewswire)
Sep-22-26 08:00AM	Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity (GlobeNewswire)
08:00AM	Loading…
Sep-15-26 08:00AM	GLP-1s Transformed Obesity. Billions Are Now Moving Into Rare Diseases That Require a Different Approach. (FinanceWire) -5.53%
Sep-10-26 08:00AM	Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting (GlobeNewswire)
Sep-03-26 08:20AM	An AI drug specialist zeroes in on rare forms of obesity (BioPharma Dive)
Aug-28-26 09:38AM	Moderna upgraded, Allstate downgraded: Wall Street's top analyst calls (The Fly)
Aug-24-26 08:00AM	Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan (GlobeNewswire)
Aug-17-26 08:00AM	Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer (GlobeNewswire)
Aug-11-26 08:00AM	Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment (GlobeNewswire)
Aug-04-26 04:01PM	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
07:01AM	Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update (GlobeNewswire)
06:55AM	Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity (GlobeNewswire)
10:34AM	Loading…
Jul-22-26 10:34AM	What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin's Rare-Obesity Opportunity (FinanceWire)
Jul-21-26 08:00AM	Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 (GlobeNewswire)
Jul-08-26 05:07PM	Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity (GlobeNewswire)
Jun-16-26 11:37AM	Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity (Proactive)
Jun-15-26 04:01PM	Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 (GlobeNewswire)
10:02AM	The Battle Against Genetic Obesity Just Sent This Biotech Stock Flying (Investor's Business Daily)
Jun-13-26 08:01AM	Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 (GlobeNewswire)
Jun-12-26 04:01PM	Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome (GlobeNewswire)
May-29-26 08:00AM	Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026 (GlobeNewswire) -5.01%
May-28-26 08:00AM	Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics (GlobeNewswire)
May-26-26 08:00AM	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-12-26 08:00AM	Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology (GlobeNewswire)
May-06-26 08:00AM	Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference (GlobeNewswire)
May-05-26 07:00AM	Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update (GlobeNewswire) +7.86%
May-04-26 08:00AM	Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society (GlobeNewswire)
06:55AM	Loading…
May-01-26 06:55AM	Rhythm Pharmaceuticals Announces IMCIVREE (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity (GlobeNewswire)
Apr-09-26 08:00AM	Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026 (GlobeNewswire)
Apr-03-26 09:00AM	Rhythm Pharmaceuticals Announces Changes to Board of Directors (GlobeNewswire)
Mar-26-26 09:01AM	Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment (GlobeNewswire)
Mar-20-26 12:58PM	PANTHERx Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE (setmelanotide) (PR Newswire)
09:24AM	Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat' (Investor's Business Daily)
03:30AM	Rhythm obesity drug wins broader use from FDA (BioPharma Dive)
Mar-19-26 06:30PM	Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity (GlobeNewswire) +5.18%
Mar-18-26 07:45AM	Aspens fresh Parkinsons data; Aldeyra tanks following FDA rejection (BioPharma Dive)
Mar-17-26 04:18PM	Rhythm Pharmaceuticals Misses The Beat In Obesity, But There's A Caveat (Investor's Business Daily)
Mar-16-26 04:01PM	Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial (GlobeNewswire)
Mar-03-26 08:24AM	Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright (TipRanks) -5.67%
Mar-02-26 09:41AM	Rhythm Pharmaceuticals Discloses 18.8% BMI Drop In Rare Obesity Patients (Benzinga)
Mar-01-26 12:30PM	Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity (GlobeNewswire)
Feb-27-26 05:45AM	Rhythm Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat) -5.45%
Feb-26-26 04:12PM	Rhythm Pharmaceuticals Inc (RYTM) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
09:55AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update (GlobeNewswire)
Feb-19-26 12:42PM	Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market (Benzinga)
10:00AM	Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:40AM	Shopify, eBay upgraded: Wall Street's top analyst calls (The Fly)
08:09AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Analog Devices, Chewy, Credo Technology, eBay, Fiverr, Shopify, Verizon, and More (24/7 Wall St.)
Feb-17-26 08:00AM	Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 (GlobeNewswire)
Feb-14-26 11:02PM	Rhythm Pharmaceuticals Eyes March 20 HO PDUFA, Highlights IMCIVREE Growth at Guggenheim Conf. (MarketBeat)
Feb-12-26 05:15PM	Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-05-26 08:00AM	Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit (GlobeNewswire)
Feb-02-26 06:12AM	This High-Flying Growth Stock Is Hiding in Plain Sight (Motley Fool) +6.31%
Jan-22-26 06:15AM	Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock? (Zacks)
Jan-09-26 08:00AM	Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones (GlobeNewswire)
Dec-12-25 05:18AM	Praxis tees up another approval filing; Geron turns to layoffs (BioPharma Dive)
Dec-11-25 01:49PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily) +12.26%
07:30AM	Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome (GlobeNewswire)
Dec-10-25 04:01PM	Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome (GlobeNewswire)
Dec-04-25 11:10AM	The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. (Barrons.com)
Nov-25-25 09:36AM	Brinker upgraded, Coinbase downgraded: Wall Street's top analyst calls (The Fly)
Nov-10-25 07:00AM	Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek 2025 (GlobeNewswire)
Nov-07-25 07:30AM	Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity (GlobeNewswire)
Nov-05-25 04:01PM	Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program (GlobeNewswire) -5.26%
Nov-04-25 04:03PM	Rhythm Pharmaceuticals Inc (RYTM) Q3 2025 Earnings Call Highlights: Revenue Growth and ... (GuruFocus.com) -7.69%
08:15AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Oct-29-25 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-28-25 10:00AM	Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-21-25 04:01PM	Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (GlobeNewswire)
Oct-09-25 01:38PM	Rhythm Pharma Stock Gears Up For Its Next Move (Investor's Business Daily)
Oct-03-25 08:48AM	Should You Expect Robust Growth Potential for Rhythm Pharmaceuticals (RYTM) Ahead? (Insider Monkey)
Sep-27-25 08:02AM	Nvidia, These Other AI Plays Lead 5 Stocks Near Buy Points (Investor's Business Daily)
Sep-21-25 10:45AM	2 Under-the-Radar Stocks That Could Soar (Motley Fool)
Sep-01-25 01:04AM	Citizens JMP Keeps Market Outperform Rating on Rhythm Pharmaceuticals (RYTM) (Insider Monkey)
Aug-28-25 11:50PM	FDA Accepts a New Drug Application From Rhythm Pharmaceuticals (RYTM) (Insider Monkey)
Aug-27-25 04:01PM	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 04:01PM	Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity (GlobeNewswire)
Aug-05-25 08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Aug-01-25 06:46AM	Canaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM) (Insider Monkey)
Jul-30-25 10:00AM	Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-29-25 10:00AM	Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline (Zacks)
Jul-22-25 04:01PM	Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 (GlobeNewswire)
Jul-21-25 09:45AM	Should You Invest in This Under-the-Radar Weight Loss Stock? (Motley Fool)
Jul-12-25 06:00PM	Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 (GlobeNewswire)
05:30AM	Investing.coms stocks of the week (Investing.com)
Jul-10-25 11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
07:38AM	Rhythms stock climbs on encouraging Phase II obesity drug data (Clinical Trials Arena)
06:21AM	Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire)
Jul-09-25 04:16PM	Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire) +36.63%
11:33AM	Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity (Investor's Business Daily)
08:00AM	Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity (GlobeNewswire)
Jul-08-25 04:01PM	Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Meeker David P	President and CEO	Sep 14 '26	Option Exercise	6.05	50,000	302,500	289,258	Sep 14 07:37 PM
Meeker David P	President and CEO	Sep 14 '26	Sale	102.67	50,000	5,133,442	239,258	Sep 14 07:37 PM
David Meeker	Director	Sep 14 '26	Proposed Sale	104.71	50,000	5,235,500		Sep 14 04:49 PM
Smith Hunter C	Chief Financial Officer	Aug 31 '26	Option Exercise	25.79	57,187	1,474,853	176,798	Sep 01 04:22 PM
Smith Hunter C	Chief Financial Officer	Aug 31 '26	Sale	105.46	62,774	6,619,913	114,024	Sep 01 04:22 PM
HUNTER SMITH	Officer	Aug 31 '26	Proposed Sale	107.17	62,774	6,727,490		Aug 31 04:32 PM
Shulman Joseph	Chief Technical Officer	Aug 13 '26	Option Exercise	6.80	2,024	13,763	20,994	Aug 17 06:00 PM
Shulman Joseph	Chief Technical Officer	Aug 13 '26	Sale	119.75	5,079	608,210	15,915	Aug 17 06:00 PM
Garfield Alastair	Chief Scientific Officer	Aug 13 '26	Sale	117.57	7,763	912,703	2,295	Aug 17 05:57 PM
Lee Jennifer Kayden	EVP, Head of North America	Aug 13 '26	Option Exercise	17.62	56,601	997,037	75,834	Aug 14 07:04 PM
Lee Jennifer Kayden	EVP, Head of North America	Aug 13 '26	Sale	117.38	75,834	8,901,531	0	Aug 14 07:04 PM
Mazabraud Yann	EVP, Head of International	Aug 12 '26	Option Exercise	6.80	46,625	317,050	112,655	Aug 14 07:01 PM
Mazabraud Yann	EVP, Head of International	Aug 12 '26	Sale	116.15	57,000	6,620,575	55,655	Aug 14 07:01 PM
ALASTAIR GARFIELD	Officer	Aug 13 '26	Proposed Sale	117.60	7,763	912,929		Aug 13 04:51 PM
JOSEPH J SHULMAN	Officer	Aug 13 '26	Proposed Sale	117.60	5,079	597,290		Aug 13 04:40 PM
Jennifer Kayden Lee	Officer	Aug 13 '26	Proposed Sale	117.60	75,834	8,918,078		Aug 13 04:39 PM
YANN MAZABRAUD	Officer	Aug 12 '26	Proposed Sale	112.84	57,000	6,432,165		Aug 12 04:34 PM
PAMELA CRAMER	Officer	Aug 11 '26	Proposed Sale	115.48	11,406	1,317,165		Aug 11 04:30 PM
PAMELA CRAMER	Officer	Aug 10 '26	Proposed Sale	115.63	3,520	407,018		Aug 10 04:33 PM
TETRAULT LYNN A.	Director	Jun 22 '26	Option Exercise	28.27	37,000	1,045,990	44,000	Jun 24 04:15 PM
TETRAULT LYNN A.	Director	Jun 22 '26	Sale	100.32	37,000	3,711,896	7,000	Jun 24 04:15 PM
LYNN TETRAULT	Director	Jun 22 '26	Proposed Sale	96.79	37,000	3,581,230		Jun 22 04:49 PM
Smith Hunter C	Chief Financial Officer	May 18 '26	Option Exercise	17.87	3,000	53,610	119,611	May 20 04:15 PM
German Christopher Paul	Corporate Controller & CAO	May 15 '26	Option Exercise	42.17	4,442	187,313	4,643	May 19 04:15 PM
German Christopher Paul	Corporate Controller & CAO	May 15 '26	Sale	92.21	4,643	428,131	0	May 19 04:15 PM
German Christopher Paul	Corporate Controller & CAO	Mar 04 '26	Option Exercise	17.97	1,500	26,955	5,753	Mar 06 04:51 PM
German Christopher Paul	Corporate Controller & CAO	Mar 04 '26	Sale	89.56	5,614	502,790	160	Mar 06 04:51 PM
CAMILLE L BEDROSIAN	Director	Mar 04 '26	Proposed Sale	90.62	64,540	5,848,744		Mar 04 04:14 PM
CAMILLE L BEDROSIAN	Director	Mar 03 '26	Proposed Sale	90.52	35,460	3,209,779		Mar 03 04:05 PM
Smith Hunter C	Chief Financial Officer	Mar 02 '26	Option Exercise	6.80	6,099	41,473	116,611	Mar 02 08:56 PM
Smith Hunter C	Chief Financial Officer	Feb 19 '26	Sale	101.26	4,385	444,004	110,512	Feb 19 09:02 PM
Smith Hunter C	Chief Financial Officer	Feb 17 '26	Sale	101.38	3,569	361,810	114,897	Feb 19 09:02 PM
Smith Hunter C	Chief Financial Officer	Feb 10 '26	Sale	103.00	2,713	279,429	122,824	Feb 12 08:56 PM
Smith Hunter C	Chief Financial Officer	Feb 11 '26	Sale	98.61	2,766	272,766	120,058	Feb 12 08:56 PM
Smith Hunter C	Chief Financial Officer	Feb 12 '26	Sale	98.23	1,592	156,380	118,466	Feb 12 08:56 PM
Smith Hunter C	Chief Financial Officer	Feb 05 '26	Sale	106.06	3,381	358,599	125,537	Feb 06 06:38 PM
Smith Hunter C	Chief Financial Officer	Feb 04 '26	Sale	105.99	3,247	344,145	128,918	Feb 06 06:38 PM
HUNTER SMITH	Officer	Feb 05 '26	Proposed Sale	107.97	18,406	1,987,296		Feb 05 04:30 PM
HUNTER SMITH	Officer	Feb 04 '26	Proposed Sale	108.29	3,247	351,618		Feb 04 04:21 PM
Cramer Pamela J.	Chief Human Resources Officer	Dec 11 '25	Option Exercise	27.35	3,350	91,622	24,164	Dec 15 04:30 PM
Cramer Pamela J.	Chief Human Resources Officer	Dec 11 '25	Sale	111.00	3,350	371,850	20,814	Dec 15 04:30 PM
PAMELA CRAMER	Officer	Dec 11 '25	Proposed Sale	104.77	3,350	350,980		Dec 11 04:25 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 20 '25	Option Exercise	27.35	3,350	91,622	24,164	Nov 24 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 20 '25	Sale	105.00	3,350	351,750	20,814	Nov 24 04:15 PM
PAMELA CRAMER	Officer	Nov 20 '25	Proposed Sale	103.15	3,350	345,552		Nov 20 04:23 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 07 '25	Option Exercise	12.36	19,351	239,184	40,165	Nov 12 04:30 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 10 '25	Option Exercise	6.80	3,515	23,902	24,329	Nov 12 04:30 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 07 '25	Sale	98.82	19,351	1,912,326	20,814	Nov 12 04:30 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 10 '25	Sale	100.00	3,515	351,500	20,814	Nov 12 04:30 PM
PAMELA CRAMER	Officer	Nov 10 '25	Proposed Sale	100.30	3,515	352,554		Nov 10 04:31 PM
PAMELA CRAMER	Officer	Nov 07 '25	Proposed Sale	98.49	19,351	1,905,880		Nov 07 04:38 PM

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

ChairmanDr. David P. Meeker M.D.

CFO & TreasurerMr. Hunter C. Smith M.B.A.

Chief Scientific OfficerDr. Alastair Garfield Ph.D.

Executive VP & Head of InternationalMr. Yann Mazabraud

Executive VP & Head of North AmericaMs. Jennifer Lee

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RYTM

Rhythm Pharmaceuticals Inc

Upgrade your Finviz experience